The effects of transdermal oestradiol and oral progestogens on haemostasis variables.
OBJECTIVE
To evaluate the effects of 1 g (1 mg oestradiol) transdermal oestradiol gel continuously combined with 10 mg medroxyprogesterone acetate orally 12 days either monthly or every third month on haemostasis variables.


METHODS
An open, parallel stratified study.


METHODS
Sahlgrenska University Hospital, Göteborg, Sweden.


METHODS
A total of 48 peri- and postmenopausal women less than 65 years of age participated in this study. Twenty-seven women, who had from 2 months to 3 years since their last period were included in group I. Twenty-one women, who were more than 3 years postmenopausal, comprised group II.


METHODS
The following parameters were determined: von Willebrand factor antigen, factor VII antigen, fibrinogen, antithrombin, protein C, protein S, plasminogen activator inhibitor activity, tissue plasminogen activator antigen, prothrombin fragment 1 + 2, thrombin-antithrombin complex and platelets.


RESULTS
Both regimens decreased fibrinogen, factor VII antigen as well as antithrombin.


CONCLUSIONS
These changes were mainly 'in an anti-thrombotic direction'. The overall impression is that the transdermally administered oestrogen in combination with an oral progestogen induced favourable, although slight changes in the haemostatic system. The possible influence of these changes on the risk of cardiovascular disease remains yet to be studied.
Kroon
U B
UB
Department of Obstetrics & Gynecology, Sahlgrenska University Hospital, Göteborg, Sweden.
Tengborn
L
L
Rita
H
H
Bäckström
A C
AC
D000279:Administration, Cutaneous; D000284:Administration, Oral; D004359:Drug Therapy, Combination; D004958:Estradiol / Q000008:administration & dosage*; D015914:Estrogen Replacement Therapy / Q000379:methods*; D005167:Factor VII / Q000378:metabolism; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage*; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism; D045167:Progesterone Congeners / Q000008:administration & dosage*; D010959:Tissue Plasminogen Activator / Q000378:metabolism; D014841:von Willebrand Factor / Q000378:metabolism
D017395:Plasminogen Activator Inhibitor 1; D045167:Progesterone Congeners; D014841:von Willebrand Factor; D004958:Estradiol; D005167:Factor VII; D005340:Fibrinogen; D017258:Medroxyprogesterone Acetate; D010959:Tissue Plasminogen Activator